Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 1Colorectal Neoplasms 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × recombinant interferon alpha 2b-like protein × Clear all
NCT02068131 2016-01-05

Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Phase 2 Unknown
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡